Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGAND: Metformin and Atorvastatin in Delaying ADT in Prostate Cancer
NCT02497638Phase 2Withdrawn
- Sponsor
- University Health Network
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) and atorvastatin in prostate cancer (PCa) (2 arms), sponsored by University Health Network. Primary endpoint: Time to disease progression at 36 months. Planned start Dec 2021; status: withdrawn.
02
Drugs
liquid metformin (Aspargo Labs)atorvastatin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02497638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497638.